|
Verici Dx PLC - Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants - Announces the publication of a peer-reviewed clinical validation study of its pre-transplant rejection assessment test, which is commercially marketed by Thermo Fisher Scientific Inc. Says the test outperformed conventional risk assessment tools in the ability to predict early acute rejection in the first two months following a kidney transplant, which enables clinicians to identify patients who may benefit from the safe minimisation of therapy while effectively managing the risk of early rejection. Says current methods, which involve standardised immunosuppressive regimens with more aggressive therapy for patients seen as high-risk, ‘have limited predictive value, which can lead to unnecessary over-suppression and risks related to toxicity, infections and malignancy.’ Current stock price: 0.40 pence, down 5.9% late on Tuesday afternoon in London 12-month change: down 65% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
